RxDoctor Payments Data

Tzy-Shiuan Kuo, MD

Interventional Cardiology · San Antonio, TXNPI 1619114295

Payments from drug & device makers

$19,546in general payments, 2019–2025

Across 228 payments — averaging $85.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$3K
  • Penumbra, Inc.$3K
  • Angiodynamics, Inc.$2K
  • EKOS Corporation$2K
  • Medtronic$2K
  • plus $5K from 23 others

What the payments were for

  • Travel & lodging$8,95546%
  • Food & beverage$8,84145%
  • Other$1,7509%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,546 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$380,308
Medicare patients
663
Services billed
3,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$261,067
AdempasRiociguat12$169,327
XareltoRivaroxaban80$102,071
FarxigaDapagliflozin Propanediol40$44,387
EntrestoSacubitril/Valsartan27$39,459
BrilintaTicagrelor49$36,656
OzempicSemaglutide22$26,234
Repatha SureclickEvolocumab23$22,423
JardianceEmpagliflozin11$9,905
Ranolazine ErRanolazine79$8,931
Metoprolol Succinate495$6,280
Prasugrel Hcl43$3,128
ClopidogrelClopidogrel Bisulfate206$2,834
Bisoprolol Fumarate88$2,391
Amiodarone Hcl40$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$261,067226 claims
BayerAdempas$193$169,32712 claims
Johnson & JohnsonXarelto$220$102,07180 claims
NovartisEntresto$392$39,45927 claims
Novo NordiskOzempic$58$26,23422 claims
Boehringer IngelheimJardiance$14$9,90511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →